<SEC-DOCUMENT>0001104659-25-105914.txt : 20251104
<SEC-HEADER>0001104659-25-105914.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251104071905
ACCESSION NUMBER:		0001104659-25-105914
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251104
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OCULAR THERAPEUTIX, INC
		CENTRAL INDEX KEY:			0001393434
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36554
		FILM NUMBER:		251446445

	BUSINESS ADDRESS:	
		STREET 1:		15 CROSBY DRIVE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		781-357-4000

	MAIL ADDRESS:	
		STREET 1:		15 CROSBY DRIVE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	I-THERAPEUTIX INC
		DATE OF NAME CHANGE:	20070315
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2530039d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:ocul="http://ocutx.com/20251104">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_ocul_ocutx.com_20251104 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20251104_20251104 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001393434 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000004" name="dei:EntityCentralIndexKey">0001393434</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ocul-20251104.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001393434</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-04</xbrli:startDate>
        <xbrli:endDate>2025-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_90B_edei--DocumentType_c20251104__20251104_zk77mawkMC1k"><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_909_edei--DocumentPeriodEndDate_c20251104__20251104_zzXVu2B3Z3ki"><ix:nonNumeric contextRef="AsOf2025-11-04" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 4, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_907_edei--EntityRegistrantName_c20251104__20251104_zrMTLTqbb3Cd"><b><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000011" name="dei:EntityRegistrantName">OCULAR
THERAPEUTIX, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Company as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20251104__20251104_zb9KVa2xcRc9"><ix:nonNumeric contextRef="AsOf2025-11-04" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 32%; text-align: center"><span id="xdx_90B_edei--EntityFileNumber_c20251104__20251104_z90eX7iLTnQ3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000013" name="dei:EntityFileNumber">001-36554</ix:nonNumeric></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="width: 32%; text-align: center"><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20251104__20251104_zNb3JTFMezVc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000014" name="dei:EntityTaxIdentificationNumber">20-5560161</ix:nonNumeric></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction
    <br/>
    of Incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission<br/>
    File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br/>
    Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90A_edei--EntityAddressAddressLine1_c20251104__20251104_zCEmp45Y63S9"><b><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000015" name="dei:EntityAddressAddressLine1">15
Crosby Drive</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_906_edei--EntityAddressCityOrTown_c20251104__20251104_zplobx1bTwKi"><b><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000016" name="dei:EntityAddressCityOrTown">Bedford</ix:nonNumeric></b></span><b>,
<span id="xdx_904_edei--EntityAddressStateOrProvince_c20251104__20251104_zJTQssyR2eOc"><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000017" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span></b><b> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20251104__20251104_zRVIr5QJKR81"><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000018" name="dei:EntityAddressPostalZipCode">01730</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices) (Zip
Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Company&#8217;s telephone number, including area
code: <b>(<span id="xdx_901_edei--CityAreaCode_c20251104__20251104_zng7zzFDCQ27"><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000019" name="dei:CityAreaCode">781</ix:nonNumeric></span></b><b>)&#160;<span id="xdx_907_edei--LocalPhoneNumber_c20251104__20251104_z6QUs55RetMf"><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000020" name="dei:LocalPhoneNumber">357-4000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%"><span id="xdx_90E_edei--WrittenCommunications_c20251104__20251104_zWvoIyR3RjX9" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-11-04" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%"><span id="xdx_90C_edei--SolicitingMaterial_c20251104__20251104_zepklzzN3UPj" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-11-04" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td>
    <td style="width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%"><span id="xdx_902_edei--PreCommencementTenderOffer_c20251104__20251104_zD26ZpqiHXN4" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-11-04" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td style="width: 96%; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20251104__20251104_zCYGQpqlgLA2" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-11-04" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td style="width: 96%; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title&#160;of&#160;each&#160;class</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading&#160;Symbol(s)</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name&#160;of
    each&#160;exchange&#160;on&#160;which<br/>
    registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span id="xdx_90D_edei--Security12bTitle_c20251104__20251104_zuywIG7800Bj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000025" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value per share</ix:nonNumeric></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span id="xdx_900_edei--TradingSymbol_c20251104__20251104_zjjd2vrkBL9f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-11-04" id="Fact000026" name="dei:TradingSymbol">OCUL</ix:nonNumeric></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: middle; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--SecurityExchangeName_c20251104__20251104_zVQuJaBAp3Wj"><ix:nonNumeric contextRef="AsOf2025-11-04" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">The
    Nasdaq Global Market</ix:nonNumeric></span></b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter)
or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Emerging growth company&#160;&#160;&#160;&#160;<span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20251104__20251104_zFls2VTKGBX3" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-11-04" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 2.02</b></span></td>
    <td style="font-size: 10pt; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results of Operations and Financial Condition. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November&#160;4, 2025, Ocular Therapeutix,&#160;Inc.
announced its financial results for the quarter ended September&#160;30, 2025. The full text of the press release is furnished as Exhibit&#160;99.1
to this Current Report on Form&#160;8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Current Report on Form&#160;8-K,
including Exhibit&#160;99.1 attached hereto, is furnished to comply with Item 2.02 of Form&#160;8-K, and shall not be deemed &#8220;filed&#8221;
for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="width: 90%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 5%"><a href="tm2530039d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="width: 95%"><a href="tm2530039d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Ocular Therapeutix,&#160;Inc., dated November&#160;4, 2025</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OCULAR THERAPEUTIX,&#160;INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November&#160;4, 2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Donald Notman</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald Notman</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Chief Operating Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUqNonxMKiKLEIletxxjSXdkdjP7pP6yVYmGC8PMvWdGiJHY0kaVyHBZpQlkWNWltAgpFsiob+gS8W4fgesp3pWxLLXtxx8Yk2PQMfNxeHX7Ptkog3kE/nISOs3An0bBAk4H4XV+TLpQOWqrZAlS53BiqlmhlfweLmSyJU3Vu/90RjaKdATB2B/sD4R+EMKRGvkifhhIklh4o748sWV61i61bi3qjoR1iZV7Zwb6L+8L02dKaQ== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2530039d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm2530039d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ocular Therapeutix&trade; Reports Third Quarter
2025 Financial Results and Business Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Recent Investor Day highlighted how AXPAXLI&trade;
is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Announced today that SOL-R achieved target randomization
of 555 subjects</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Exceptional execution and retention in AXPAXLI
wet AMD registrational program continue with topline data on track for SOL-1 in 1Q 2026 and SOL-R in 1H 2027</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Registrational HELIOS program for AXPAXLI in
NPDR expected to begin imminently using a novel primary endpoint</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Cash balance of $344.8 million as of September&nbsp;30,
2025, together with net proceeds of ~$445 million from October&nbsp;2025 equity offering, with expected runway into 2028</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BEDFORD, MA, November&nbsp;04, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix,&nbsp;Inc.
(NASDAQ: OCUL, &ldquo;Ocular&rdquo;), an integrated biopharmaceutical company committed to redefining the retina experience, today reported
financial results for the third quarter ended September&nbsp;30, 2025 and provided recent business highlights. Separately, Ocular announced
today that its SOL-R registrational trial of AXPAXLI&trade; (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD)
has achieved its randomization target of 555 subjects. Ocular will continue to allow randomization of subjects currently in the loading
phase of the trial to maintain its commitment to both patients and investigators, with topline data remaining on track for the first half
of 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;At Ocular Therapeutix, we are courageous, bold, opportunistic,
and driven by a refusal to accept the status quo. We think differently about what is possible by designing creative, de-risked clinical
programs that are tightly aligned with the FDA, while advancing patient care,&quot; said <B>Pravin U. Dugel, MD, Executive Chairman, President
and Chief Executive Officer of Ocular Therapeutix. </B>&ldquo;At our September&nbsp;Investor Day, we presented our HELIOS program for
AXPAXLI in diabetic retinopathy which embodies this philosophy: we&rsquo;ve designed a novel ordinal DRSS endpoint that reflects real-world
treatment goals, potentially increases the probability of success, and is agreed to by the FDA through our Special Protocol Assessment
(SPA) agreement for HELIOS-2. We also shared that the true market opportunity for anti-VEGFs may extend far beyond today&rsquo;s approximately
$15 billion annual market. The opportunity for expansion could be driven by the millions of wet AMD patients who discontinue treatment
or are undertreated because current options are not sustainable. Moreover, we also see opportunity for expansion in NPDR, a disease three
times as prevalent as wet AMD with no standard-of-care in use today, and DME. Across every dimension, from trial design and patient selection
to execution and product profile, we embody our philosophy of being courageous, bold and opportunistic.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dr.&nbsp;Dugel</B> concluded, &ldquo;We are in an enviable financial
position, augmenting our cash of $344.8 million as of September&nbsp;30<SUP>th</SUP> with our recent equity offering of approximately
$445 million in net proceeds. This strong cash position provides flexibility to fund our registrational programs in wet AMD and diabetic
retinopathy, initiate our SOL-X extension study and advance infrastructure development to support increased manufacturing capacity and
future growth. Guided by the triad of a potential superiority label, market expansion, and immediate adoptability, we remain highly confident
and enthusiastic in our ability to redefine the retina experience.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Achievements and Upcoming Milestones:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SOL-1 (Phase 3, wet AMD) superiority trial on track for Q1 2026 topline
data with exceptional retention and protocol adherence. </B>The SOL-1 superiority trial, conducted under an SPA agreement with the U.S.
Food and Drug Administration (FDA), has the potential to support the first label with a superiority claim over a single dose of aflibercept
(2 mg) for any wet AMD product. Retention in the trial continues to be outstanding, with &gt;95% of randomized subjects remaining on-study
to date; and rescues reviewed under masking show &gt;95% of rescue events have met pre-established protocol-defined criteria. Oversight
by an independent data and safety monitoring committee (DSMC) has not identified any safety signals in SOL-1 to date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SOL-R (Phase 3, wet AMD) non-inferiority trial achieves target randomization
of 555 subjects and remains on track for 1H 2027 topline data. </B>Ocular will continue to allow randomization of previously enrolled
subjects currently in the loading phase of the trial to maintain its commitment to both patients and investigators. The SOL-R non-inferiority
trial complements SOL-1 with the potential to provide clinically relevant data that support the immediate adoption of AXPAXLI into clinical
practice, if approved. SOL-R incorporates a comprehensive 24-week screening and loading phase to exclude subjects with early persistent
fluid or significant retinal fluid fluctuations, resulting in the randomization of subjects with less variability in visual acuity, thereby
de-risking the patient population. In addition to patient selection, Ocular believes the inclusion of a singular Week 56 primary endpoint
in SOL-R is potentially favorable as subjects will have received their most recent aflibercept or AXPAXLI injection eight weeks prior,
at Week 48.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SOL-X (wet AMD) open label extension study to evaluate AXPAXLI&rsquo;s
ability to improve long-term outcomes and the impact of delayed initiation of AXPAXLI. </B>Subjects who have completed two-year follow-up
in either SOL-1 or SOL-R will have an opportunity to enroll in the SOL-X study for an additional three years. SOL-X outcomes may further
expand AXPAXLI&rsquo;s potential by highlighting the need to start AXPAXLI treatment early or potentially risk worse long-term visual
outcomes due to potential fibrosis and atrophy that may be seen with pulsatile treatments. By reducing the treatment burden and potentially
improving long-term outcomes, Ocular believes the data from SOL-X could increase both short-term and long-term patient retention significantly,
thereby expanding the market opportunity in wet AMD.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Imminent plans to initiate HELIOS registrational program (Phase 3, NPDR),
leveraging a novel primary endpoint and targeting a broad DR label.</B> These complementary superiority trials will leverage a novel ordinal
 &ge;2-step diabetic retinopathy severity score (DRSS) primary endpoint. Ocular aligned with the FDA on this novel endpoint in its SPA
agreement for HELIOS-2. This endpoint was designed to increase the probability of clinical and regulatory success for the HELIOS Phase
3 trials and provide clinically relevant data that aligns with retina specialist&rsquo;s treatment goals in this indication. The new endpoint
measures changes across the DRSS spectrum, including disease improvement, stability, and worsening. By allowing every patient to contribute
data to the statistical analysis, a smaller trial size can achieve statistically significant outcomes relative to the size required for
a binary analysis. Ocular plans to target a broad label in DR by including subjects with non-center-involved diabetic macular edema (non-CI-DME)
in its Phase 3 program. Ocular is preparing to initiate the HELIOS registrational program imminently with the goal of evaluating 6- and
12-month dosing intervals.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Completed an equity financing with approximately $445 million of net proceeds
in early October&nbsp;2025 to support planned operations into 2028.</B> Proceeds from the offering allow the Company to opportunistically
expand into diabetic retinal disease, fund its planned SOL-X long-term extension trial in wet AMD, and invest in infrastructure, including
capital expenditures to support manufacturing and other pre-commercial activities associated with AXPAXLI, if approved.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Third Quarter Ended September&nbsp;30, 2025, Financial Results:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Total cash and cash equivalents</B> were $344.8 million as of September&nbsp;30,
2025, excluding the net proceeds of approximately $445 million from an underwritten offering of common shares which the Company closed
and settled on October&nbsp;1, 2025. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA<SUP>&reg;</SUP>,
the Company believes that its current cash balance, including net proceeds from the offering, is sufficient to support its planned expenses,
debt service obligations, and capital expenditure requirements into 2028. This cash projection factors in the expected topline data readout
from both the SOL and HELIOS registrational trials, the initiation of the SOL-X wet AMD open label extension study, plus investment in
pre-commercial activities associated with AXPAXLI but does not include the full expenses the Company anticipates it needs to support the
commercialization of AXPAXLI, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Total net revenue</B> was&nbsp;$14.5 million&nbsp;for the third
quarter of 2025, a 5.8% decrease as compared to total net revenue of $15.4 million in the comparable quarter in 2024. Total net revenue
includes both gross DEXTENZA product revenue, net of discounts, rebates, and returns, which the Company refers to as net product revenue,
and collaboration revenue. The reduction in net revenue was due to a significantly more challenging reimbursement environment for DEXTENZA
in 2025, partially offset by robust performance by the Ocular commercial team to drive unit demand for DEXTENZA. Compared to the second
quarter of 2025, DEXTENZA end-user unit sales grew 9.7% while DEXTENZA net product revenue increased by 8.5% in the third quarter of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research and development expenses</B> for the third quarter of 2025
were $52.4 million versus $37.1 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses associated
with the ongoing SOL-1 and SOL-R Phase 3 clinical trials, and preparations to initiate the SOL-X and HELIOS trials, with additional personnel
and professional services to support these clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Selling and marketing expenses</B> were $13.1 million for the third
quarter of 2025, as compared to $10.6 million for the comparable quarter of 2024, primarily reflecting an increase in personnel-related
costs related to the expansion of our marketing team for AXPAXLI, including stock-based compensation, an increase in professional fees,
including costs related to corporate branding, and an increase in facility-related and other costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General and administrative expenses</B> were $16.0 million for the
third quarter of 2025, as compared to $12.2 million for the comparable quarter of 2024, primarily due to an increase in personnel-related
costs, including stock-based compensation expense, and an increase in facility-related and other costs, partially offset by a decrease
in professional fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net loss for the third quarter of 2025</B> was&nbsp;$(69.4) million,
or a net loss of&nbsp;$(0.38)&nbsp;per share on both a basic and diluted basis, compared to a net loss of&nbsp;$(36.5) million, or a net
loss of&nbsp;$(0.22)&nbsp;per share on a basic and diluted basis, for the comparable quarter of 2024. The net loss in the third quarter
of 2025 includes a net loss from the change in fair value of our derivative liability of $(1.4) million, which is comprised of a non-cash
loss from fair value measurement of the derivative liability associated with the Barings Credit Facility of $(0.9) million, and expense
related to actual royalty fees under the Barings Credit Facility of $(0.5) million. The net loss for the third quarter of 2024 includes
a net gain from the change in the fair value of our derivative liability of $7.1 million, which is comprised of a $7.6 million non-cash
gain from fair value measurement of the derivative liability associated with the Barings Credit Facility, partially offset by $(0.5) million
expense related to actual royalty fees under the Barings Credit Facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding shares</B> as of&nbsp;October&nbsp;31, 2025, were approximately
213.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference Call and Webcast Information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ocular Therapeutix will host a conference call and webcast on Tuesday,
November&nbsp;4, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September&nbsp;30,
2025. To access the call, please dial: <I>1-877-407-9039 (U.S.) or 1-201-689-8470 (International)</I>. The live and archived webcast can
also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A
replay of the webcast will be archived for at least 30 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About AXPAXLI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>AXPAXLI&trade; (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small
molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet AMD, diabetic
retinopathy, and other retinal diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the SOL-1 Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>The registrational Phase 3 SOL-1 trial (NCT06223958) is designed to evaluate the safety and efficacy of AXPAXLI in a multi-center,
double-masked, randomized (1:1), parallel group study that involves more than 100 clinical trial sites located in the U.S. and Argentina.
In December&nbsp;2024, the trial completed randomization of 344 evaluable treatment-na&iuml;ve subjects with a diagnosis of wet AMD in
the study eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The superiority study has an eight-week loading segment prior to randomization.
During the loading segment, subjects who have 20/80 vision or better and a central subfield thickness (CSFT) of &le;500 &mu;m receive
two doses of aflibercept (2 mg) at Week -8 and Week -4. Subjects who achieve best corrected visual acuity (BCVA) of 20/20 at Day 1 or
gain at least 10 early treatment diabetic retinopathy study (ETDRS) letters at Day 1 along with a CSFT of &le;350 &mu;m are then randomized
to receive a single dose of AXPAXLI or a single dose of aflibercept (2 mg). At Week 52 and at Week 76, all subjects are re-dosed with
their respective initial treatment of AXPAXLI or aflibercept (2 mg). Subjects will be followed for safety until the end of Year 2. Throughout
the study, subjects are assessed monthly. Trial subjects and designated study personnel will remain masked through the end of Year 2.
The clinical trial protocol requires that, during the study, subjects in either arm meeting pre-specified rescue criteria will receive
a supplemental dose of aflibercept (2 mg).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary endpoint of SOL-1 is the proportion of subjects who maintain
visual acuity, defined as a loss of &lt;15 ETDRS letters of BCVA, at Week 36. Subjects will continue to be evaluated for durability up
to Week 52. The study is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the SOL-R Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>The registrational Phase 3 SOL-R trial
(NCT06495918) is designed to evaluate the safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized (2:2:1), three-arm
study that includes sites located in the U.S., Argentina,&nbsp;India, and Australia. The trial is intended to randomize approximately
555 subjects who are treatment-na&iuml;ve or were diagnosed with wet AMD in the study eye within about four months prior to enrollment.
Further, to qualify for screening, a subject&rsquo;s study eye must have a BCVA ETDRS letter score of &ge;34 (~20/200).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This non-inferiority trial reflects a patient enrichment strategy over
the six months prior to randomization that includes three screening doses of any anti-VEGF therapy, excluding brolucizumab-dbll, and monitoring
to exclude those subjects with early persistent fluid or significant retinal fluid fluctuations. Subjects who continue to meet eligibility,
defined as a CSFT of &le;350 &mu;m at Week -12 and Week -8 with &le;35 &mu;m CSFT increase from the lowest CSFT at any prior visit, will
enter a run-in period and receive two loading doses of aflibercept (2 mg) prior to Day 1. Subjects in the first arm receive a single dose
of AXPAXLI at Day 1 and are re-dosed at Weeks 24, 48, and 72. Subjects in the second arm receive aflibercept (2 mg) on-label every eight
weeks. Subjects in the third arm receive a single dose of aflibercept (8 mg) at Day 1 and are re-dosed at Weeks 24, 48, and 72, aligned
with the AXPAXLI treatment arm for adequate masking. Subjects will be followed for safety until the end of Year 2. Throughout the study,
subjects are assessed monthly. Trial subjects and designated study personnel will remain masked through the end of Year 2. Subjects in
any arm that meet pre-specified rescue criteria will receive a supplemental dose of aflibercept (2 mg). The pre-specified rescue criteria
include a &gt;5-letter loss in visual acuity plus a &ge;75 &mu;m increase in CSFT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary endpoint of SOL-R is to demonstrate non-inferiority in
mean BCVA change from baseline between the AXPAXLI and on-label aflibercept (2 mg) arms at Week 56. As per the protocol agreed to by the
FDA, the non-inferiority margin for the lower bound is -4.5 letters of mean BCVA when compared to aflibercept (2 mg) dosed every eight
weeks. In a written Type C response received in August&nbsp;2024, and a subsequent written response received in December&nbsp;2024, the
FDA agreed that the SOL-R repeat dosing wet AMD study, with a primary endpoint at Week 56, should be appropriate as an adequate and well-controlled
study in support of a potential New Drug Application and product label for wet AMD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the SOL-X Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SOL-X trial is a multi-center, 36-month open-label extension trial
designed to evaluate the long-term safety, efficacy, and disease modifying potential of AXPAXLI in wet AMD for subjects who have completed
either the SOL-1 or SOL-R studies through the end of the Year 2 visit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All subjects will be given AXPAXLI every 6 months starting at Week
0 (Week 104 in SOL-1, Week 96 in SOL-R), at Week 24, Week 48, Week 72, Week 96, and Week 120. Subjects are assessed at Week 4 and Week
12, then every 12 weeks thereafter. Additional visits can be conducted with supplemental anti-VEGF injection administered based on investigator
discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary objectives of SOL-X are to evaluate the long-term safety
of AXPAXLI; to explore long-term visual outcomes, including visual acuity and the incidence and/or progression of fibrosis and macular
atrophy; and to evaluate the impact of delayed initiation of AXPAXLI in patients who initially were randomized to receive aflibercept
in either SOL-1 or SOL-R.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the HELIOS-2 Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The planned registrational Phase 3 HELIOS-2 trial is designed to evaluate
the safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized (1:1), parallel group study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This trial is a superiority study of AXPAXLI in approximately 432 subjects
with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME).
Eligible subjects are randomized to receive a single dose of AXPAXLI or a single dose of ranibizumab (0.3 mg) at Day 1. At Week 52, all
subjects are re-dosed with their respective initial treatment of AXPAXLI or ranibizumab (0.3 mg). Subjects will be followed for safety
until the end of Year 2. Throughout the study, subjects are assessed monthly. Trial subjects and designated study personnel will remain
masked through the end of Year 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary endpoint of HELIOS-2 is the ordinal DRSS 2-step change
status at Week 52 from baseline (&ge;2-step improvement, &ge;2-step worsening, less than 2-step change in either direction). The study
is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the HELIOS-3 Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The planned registrational Phase 3 HELIOS-3 trial is designed to evaluate
the safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized (1:1:1), three-arm study. This trial will be the second
superiority study of AXPAXLI in approximately 930 subjects with moderately severe to severe non-proliferative diabetic retinopathy (NPDR)
without center-involved diabetic macular edema (CI-DME).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subjects in the first arm receive a single dose of AXPAXLI at Day 1
and are re-dosed at Week 24. Subjects in the second arm receive a single dose of AXPAXLI at Day 1 and sham at Week 24. Subjects in the
third arm receive sham at Day 1 and at Week 24, aligned with the AXPAXLI treatment arms for adequate masking. Throughout the study, subjects
are assessed every 12 weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary endpoint of HELIOS-3 is the ordinal DRSS 2-step change
status at Week 52 from baseline (&ge;2-step improvement, &ge;2-step worsening, less than 2-step change in either direction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Wet AMD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wet age-related macular degeneration (wet AMD) is a leading cause of
severe, irreversible vision loss affecting approximately 14.5 million individuals globally and 1.8 million in the United States alone.
Wet AMD causes vision loss due to abnormal new blood vessel growth and hyperpermeability and associated retinal vascularity in the macula,
which is primarily stimulated by local upregulation of vascular endothelial growth factor (VEGF). Without prompt and continuous treatment
to control this exudative activity, patients develop irreversible vision loss. With proper treatment, patients may maintain visual function
for a period of time and may temporarily regain lost vision. Challenges with current therapies include pulsatile, repeated intraocular
injections, treatment-related adverse events and up to 40% patient discontinuation within one year of initiating treatment with continued
disease progression. Taken together, these factors lead to undertreatment and a lack of long-term vision improvement for patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Diabetic Eye Disease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Diabetic eye disease is an increasingly prevalent global health concern,
driven by the rapidly rising number of individuals diagnosed with diabetes each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Diabetic retinopathy (DR) is the most common category of retinal diseases,
affecting over an estimated 103 million people worldwide. DR is a progressive condition in which retinal blood vessels are damaged following
a cascade of events triggered by chronically elevated levels of blood glucose. As many as half of all diabetic patients are expected to
develop some form of DR in their lifetime. DR can progress from the non-proliferative (NPDR) stages to the proliferative (PDR) stage characterized
by the growth of abnormal new blood vessels. Fewer than 1% of the 6.4 million NPDR patients in the U.S. receive treatment today, despite
the availability of anti-VEGF therapies approved for the indication, largely due to the burden of frequent injections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Diabetic macular edema (DME) is also a leading cause of vision loss
in the working-age population. DME, the result of an accumulation of fluid in the macula that can afflict patients with diabetes, can
occur at any stage of DR. In patients with DME, blood vessels in the eyes leak and start to swell, which can cause vision loss or blindness.
Anti-VEGF drugs are approved to treat DME, but these treatments typically require frequent intravitreal injections, placing a significant
burden on patients and physicians alike.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Ocular Therapeutix,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ocular Therapeutix,&nbsp;Inc. is an integrated biopharmaceutical company
committed to redefining the retina experience. AXPAXLI&trade; (also known as OTX-TKI), Ocular&rsquo;s investigational product candidate
for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX&trade; proprietary bioresorbable hydrogel-based formulation
technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), with a Phase 3 clinical
program for non-proliferative diabetic retinopathy (NPDR) planned to be initiated imminently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ocular&rsquo;s pipeline also leverages the ELUTYX technology in its
commercial product DEXTENZA<SUP>&reg;</SUP>, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following
ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric
patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that
has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating
next steps for the OTX-TIC program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Explore the Company&rsquo;s new corporate branding and follow the Company
on its website, LinkedIn, or X.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DEXTENZA<SUP>&reg;</SUP> is a registered trademark of Ocular Therapeutix,&nbsp;Inc.
The Ocular Therapeutix logo, AXPAXLI&trade;, ELUTYX&trade;, and Ocular Therapeutix&trade; are trademarks of Ocular Therapeutix,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Any statements in this press release
about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA, the development and regulatory
status of the Company&rsquo;s product candidates, the timing, design, enrollment, randomization, conduct and retention of subjects in
the Company&rsquo;s clinical trials, including the Company&rsquo;s SOL-1 and SOL-R Phase 3 clinical trials of AXPAXLI (also known as
OTX-TKI) for the treatment of wet AMD, the Company&rsquo;s planned SOL-X clinical trial of AXPAXLI for the treatment of wet AMD, and
the Company&rsquo;s planned HELIOS-2 and HELIOS-3 Phase 3 clinical trials of AXPAXLI for the treatment of NPDR; the Company&rsquo;s plans
to advance AXPAXLI, OTX-TIC, and its other product candidates; the potential utility or adoption, if approved, of any of the Company&rsquo;s
product candidates; the Company&rsquo;s cash runway and the sufficiency of the Company&rsquo;s cash resources; and other statements containing
the words &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;estimate&rdquo;, &ldquo;expect&rdquo;, &ldquo;intend&rdquo;, &ldquo;designed&rdquo;,
 &ldquo;goal&rdquo;, &ldquo;may&rdquo;, &ldquo;might&rdquo;, &ldquo;plan&rdquo;, &ldquo;predict&rdquo;, &ldquo;project&rdquo;, &ldquo;target&rdquo;,
 &ldquo;potential&rdquo;, &ldquo;will&rdquo;, &ldquo;would&rdquo;, &ldquo;could&rdquo;, &ldquo;should&rdquo;, &ldquo;continue&rdquo;,
and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors.
Such forward-looking statements involve substantial risks and uncertainties that could cause the Company&rsquo;s development programs,
future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the timing and costs involved in commercializing any product or product candidate
that receives regulatory approval; the ability to retain regulatory approval of any product or product candidate that receives regulatory
approval; the ability to maintain and the sufficiency of product, procedure and any other reimbursement codes for DEXTENZA; the initiation,
design, timing, conduct and outcomes of ongoing and planned clinical trials, including the SOL-1 trial, the SOL-R trial, the planned
SOL-X trial, the planned HELIOS-2 trial, and the planned HELIOS-3 trial; the risk that the FDA will not agree with the Company&rsquo;s
interpretation of the written agreements under the Special Protocol Assessments for AXPAXLI, including for the SOL-1 and HELIOS-2 trials;
the risk that even though the FDA has agreed with the overall design of the SOL-1 and HELIOS-2 trials, the FDA may not find that the
data generated by the applicable trial supports potential marketing approval; the risk that the FDA might not agree to the Company&rsquo;s
design, protocol, and statistical analysis plan of the SOL-R trial or the planned HELIOS-3 trial; the risk that the Company and the FDA
may not agree on the registrational pathway for any of its product candidates; uncertainty as to whether the data from earlier clinical
trials will be predictive of the data of later clinical trials, particularly later clinical trials that have a different design or utilize
a different formulation than the earlier trials, whether preliminary or interim data from a clinical trial (including masked safety or
masked rescue data from the Company&rsquo;s SOL-1 trial or SOL-R trial) will be predictive of final data from such trial, or whether
data from a clinical trial assessing a product candidate for one indication will be predictive of results in other indications; uncertainty
as to whether data from the Company&rsquo;s SOL-X trial will demonstrate clinically meaningful, long-term benefits; uncertainties regarding
the potential commercial advantages and/or position of the Company&rsquo;s product candidates; availability of data from clinical trials
and expectations for regulatory submissions and approvals; the Company&rsquo;s scientific approach and general development progress;
uncertainties inherent in estimating the Company&rsquo;s cash runway, future expenses and other financial results, including its ability
to fund future operations, including clinical trials; the Company&rsquo;s existing indebtedness and the ability of the Company&rsquo;s
creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default; and other factors discussed
in the &ldquo;Risk Factors&rdquo; section contained in the Company&rsquo;s quarterly and annual reports on file with the Securities and
Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company&rsquo;s views as
of the date of this press release. The Company anticipates that subsequent events and developments may cause the Company&rsquo;s views
to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically
disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These
forward-looking statements should not be relied upon as representing the Company&rsquo;s views as of any date subsequent to the date
of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors&nbsp;&amp; Media</B><BR>
Ocular Therapeutix,&nbsp;Inc.<BR>
Bill Slattery<BR>
Vice President,&nbsp;Investor Relations<BR>
<U>bslattery@ocutx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ocular Therapeutix,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and per share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">September&nbsp;30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2025</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; width: 74%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">344,772</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">392,102</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Accounts receivable, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,768</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,388</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">Inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,488</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,040</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,952</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,457</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">386,980</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">440,987</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,954</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,389</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Restricted cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,614</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,614</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Operating lease assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,334</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,945</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">410,882</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">457,935</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,260</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,176</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Accrued expenses and other current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,272</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">35,117</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Deferred revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">128</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Operating lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,762</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,933</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">49,294</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">41,354</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Operating lease liabilities, net of current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,629</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,345</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,962</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,246</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Deferred revenue, net of current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Notes payable, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">70,617</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">68,505</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Other non-current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">151</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">141</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">152,653</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">142,591</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Commitments and contingencies</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at September&nbsp;30,&nbsp;2025 and December&nbsp;31,&nbsp;2024, respectively</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Common stock, $0.0001 par value; 400,000,000 shares and 400,000,000 shares authorized and 174,949,558 and 157,749,490 shares issued and outstanding at September&nbsp;30,&nbsp;2025 and December&nbsp;31,&nbsp;2024, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,350,580</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,206,412</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,092,369</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(891,084</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">258,229</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">315,344</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">410,882</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">457,935</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ocular Therapeutix,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations and Comprehensive
Loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands, except share and per share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Nine Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">September&nbsp;30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">September&nbsp;30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenue:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; width: 48%; text-align: left">Product revenue, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">14,544</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">15,347</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">38,573</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">46,441</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Collaboration revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">128</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left">Total revenue, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,544</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,425</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">38,701</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">46,641</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Costs and operating expenses:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: red">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: red; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: red; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: red; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Cost of product revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,774</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,561</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,980</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">52,358</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37,054</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">146,296</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">86,646</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Selling and marketing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,088</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,573</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,965</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,750</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,235</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">46,717</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">46,054</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left">Total costs and operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">83,242</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">61,423</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">238,958</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">167,846</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(68,698</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(45,998</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(200,257</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(121,205</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: red">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: red; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: red; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: red; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,729</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,653</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,012</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,611</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,002</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,224</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,003</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(10,471</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Change in fair value of derivative liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,447</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,076</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,066</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,103</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Loss on extinguishment of debt</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(27,950</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Gain on sale of property and eqipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">29</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left">Total other income (expense), net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(720</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,505</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,028</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(23,913</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(69,418</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(36,493</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(201,285</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(145,118</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Net loss per share, basic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.94</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Weighted average common shares outstanding, basic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">183,919,808</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">166,992,735</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">175,356,729</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">154,990,112</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Net loss per share, diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.94</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Weighted average common shares outstanding, diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">183,919,808</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">166,992,735</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">175,356,729</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">154,990,112</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ocul-20251104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaGLSbOdzZR+OYkxtmB1bQnKPycig4S9eyYrJnZGAeoJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ocul="http://ocutx.com/20251104" elementFormDefault="qualified" targetNamespace="http://ocutx.com/20251104">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://ocutx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ocul-20251104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ocul-20251104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ocul-20251104_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ocul-20251104_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="ocul-20251104.xsd#Cover" roleURI="http://ocutx.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://ocutx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2530039d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2530039d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !L 4(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJU-R<YZN[_K#@KQJ\ J_&648[C_P>C3R'(>!ZO"<Z"A#BRI4XOC*+^M5J/\
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M5!U!1110 4444 %%%% $"J" 5Z'@XR2.OZ<_AG'.*_F>_P""TO\ P7H\+_\
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M;P[KB;47_A(O#/B.TO WF[;D!R7_ ),/VG/^#2CQ_J/QK&J?LB_'_P"'FB?
M77;]+B^\/?&NX\:_\+%^&NG.5_XEGAV[T+PWXKMOB)"$)E1_%5QX-DP1;.GV
MK=XH/#1\4. N,,&\!Q3D:R&*]Z$U:<&UI[K2YX3CK:RNXWM)ZP716X2XAX>D
M\7DLT^_+>Z[:/>+V>CZ:(_K_ /V0/VHOAM^VI^S7\*_VG/A2=:B\!_%[P[?Z
MSI5IXALTL/$.B:GH^MZOX9\2^']7MP'$>K^&/$NA:QX=N "P$ND.Y=@0:YS]
MOSXA^+?A#^PO^V-\4O >J3^&_'GP\_9:^/'C/P;KMOY4E]H?BCPY\,/$FM>'
MM;3./^1?UJ*&Z"#>J^3NR"V3/^Q!^RAX)_89_95^"_[+W@#4[_Q#X<^%'AV\
MM6U_64%OJ7BOQ9XBUG5_&WCCQ(^F$R0Z))XD\>Z_XA\0Q^'[61X/#T=P+".6
M6.V\P\5_P5#(?_@FM^WZWK^QO^T@<?3X.>*C_.OYRPT<#+B&,<"N;)WQ2E%5
M+J3H>VIIJ7-=_!R\U_B=^9-N2/U?_:O[*;Q>DN5MV>SM\GMUTOIL?Y)'A?XG
M?$;P7\1=(^,/A;QOXBT3XKZ#XO'C_2/B#:ZOJX\36/CP:P==_MK^VAU\0GQ#
M]YL88DELDYK_ &9?A7XDO/&WPQ^&_C74H;:VO_%_@3POXHO+6V8_8UO]>T32
M]8(0D$XB>4B(G)";@"?ES_BP5_M$?L[#_C'WX''O_P *?^&@_P#+,T2OW7QW
MPT8X;@V3C'F]G47-9<W+'EGR\V_+S/FM>W-JDG=O\V\.)7_MC?5I;]>^RMM_
M727XW^)]2\&?!KXO>,_#LEO'X@\'_#+QWXDTB>>W-VBZGH'A+6-9TIF3<HE1
M)XE9D.[>K.A#!SN_QK=7^)WQ'UWXB7'Q;U3QQXMU'XH77C _$"[^(=UXCUD^
M.#X\_MD:]_PF7]N?\C*?$0\1?,/%'!# $8.*_P!D']IG_DV[X_\ _9%?BA_Z
MA>NU_C!T_ C#*6%XRDDK\E-7LN;E?-.W-O:^MKV3UM?4?B/*W]C_ #2UZM6O
M]SMI9^=KI_[&O[#GQ%\4_%[]BK]D+XK^-M1&I>-OBG^S%\!OB#XNU, ?Z;XH
M\;?"SPQXCU^_1.A$NM:M,^,  /Z8KZU/5_Q_]"%?#'_!,?\ Y1N_\$^?^S)O
MV4O_ %0G@.ON<]7_ !_]"%?@.)_Y&&86LE[2222222K5DDDDDE9+1))6LDEH
M?IF&_P!TR[_!'Y^ZC_&,_:0^+?CWXY?'[XP?&#XE^(K_ ,4^/_'7Q&\2^)?$
M>NZK>MJ0##5@O]D+YC,R^'?"P1?#?@WPPI"^#?!^A)&D:QJ /]3K_@CS\0_&
MOQ6_X)H?L;>//B'K^I>*?&>M?!O3[?5/$>KZA_:FJ:XFBZIJ>@Z5/JVL;T&N
M:T^C:'!]JUT%!<W!FNG61YV9O\G?QJ,^,?&/_8RZL?RUHFO]6;_@AR,_\$G?
MV(/;X0\_0^+/$=?T5XWX7!T^'N'XPC%1=5PLDDHP5"5E&RTBO9Q2BK*T8JUH
MQ2_+/#N;GG&<-Z.,$N][26O9==%HKNUKL_6&BBBOYO/UT*@8)CJ<'KD?XXIV
M<H/KCZCK_A7P#_P4M_:PM?V*/V)/VA_VDS>VUGK_ ,/_  %JMI\.UNH1J?VO
MXI>.63P/\*HSI1*?:()?B)KF@K=JAEV^&DUJ;!5)%%8>AB,3BX87#I<TG&$;
M+5RF[12T?XZ+=M;G-B,2L-AI8J2TC&[M\S^(O_@ME_P6[_:N\>?M=_%'X$?L
MM_'CQY\#?@#\!O%FJ?#.RN_@OXLUCP9XJ\=>/?!>O+I?C[QIKWCG0XHO%1T!
MO%:ZSX;\'>&_"_BU/"4WA'PZD\RF;Q9\O:?\$*O^"W7[5?AS]K?X8_LP?M1_
M&WQI\=O@U\?O$6G?#31=<^+/B;6?&/C7X;_%'7%)\"ZMH_CO7HIO$^O^&_&'
MB(Z/X3?PUXJ\4/)$GB-I(0'\)_\ %8_S@_ +X2>)?VF_VB/A'\%M(NK^7Q7\
M=/BYX%\!R:W(1J%]#?\ C?QD-$\0:[KS,0%$:ZT_BB1G)4*A)/<9/Q+\"^-_
MV<?CEX_^&FJ7UQHWQ'^!'Q3\4>#+K5M(N_[/U&Q\=?"OQD=".N:'CD8\0Z'N
M4@$C[PY -?V&^!>%O['_ -5%E5/ZZL/=57"C]86])8AQM[3V?UG5I35)S3H)
MVLC\-_UDSA8W^V?LMV?Q-+KM>S?+TM>SN];M?[2"A,=3@=,#_#-3U\5_L"_M
M1Z5^V?\ L>?L\?M*V,EJ;CXH_#72]0\6V=FR#3])\?Z,'\.?%'0TC.=R>&/B
M'H?B/PWN! 5K1R00>/L_.$/UQ]!U_P :_CRO0Q&'Q4\+B%[T7.$KI74H-QDG
M;3=.W=:]S]RP^)6)PT<5%:2C=7^7^?X#'Z'_ '1_Z"*_Q]?^"D?QB\>_'3]O
M+]K7XA?$/6]1UG79_P!H+XGZ'8K=WG]I?V#X6T'QIK^@^!/!>AGOX=\)^'-#
MT/POQU(YY//^P4_0_P"Z/_017^,_^V!_R=G^U%_V<)\9?_5F^(*_</ B,7GV
M;SY5SK#4XJ5ES*,JLW**>Z4G&+:6[BKWLC\_\17_ +%E?;VDO_28GSN89^T/
MYBE$(B//0^A_SC./4XQUK_3T_P"#: *?^"0W[/YV@L/&GQ[P3Z?\+L\>X'Y_
MY]?U=_:;_9@^#'[7GP1\;? KXY>#M&\6^!_&&DZA:+'J&F:3?7_AG5;C3KJW
MT7QGX1N9K9O[ \4^%99!=^%O$$(BN[2X@PYE21Q)[V8^,];*\ZSG)<5D=*<(
MUYTIOVTHU(QA9.:C[)Q<DY*\'.-E]J]CR<-P#'%Y2L7_ &O*[CS+W?=ZZ7YK
M]-]>^A_G+_\ !)3_ (+D_M"_L$?$CP?X#^+GC3Q9\8OV.]3NM,T3Q;\/]?U#
M6O$>K_#+2V78?&OP/EUL[_#K>%!P?A@C)X.\9JSJ@3QR_P#PF1_TU_#>O:#X
MNT+1O%7AW5;36O#GB32].USP_JNG7*WFF:UI>KPQZOI.K:=("RO'/;R)/"^T
M9B96),:)C_%H\?>%I_ GC?QAX'O[ZWU.X\&^,/$_A>\U?2B3IE^="UHZ"VLZ
M'QR"W(ZX_6O]2_\ X($?$3Q#\3O^"17[%OB/Q3,)]1TOP/XV^'EFYF+;O#7P
MF^,/C_X4^"/F'7_BE/!&A*I/W3N49SMKQ?&3A?+L!A<GXEP$%#ZW*<:J@E!5
M*BI3G[6225ZCC%QE)ZS5G-RDE)^EP'G>,DY91C%\%Y1VT5U[JV5K]$DET21^
MR]%%%?A)^FA1110 4444 ?RB?\';7B_4M'_8!^"7@[3IKVTM?%W[57A:YU<6
MH BU'2M!^%GQ7(T?5.H\H>(=<T+Q*"-H+^'7&#C<?Y(?^")7PN\.?&7_ (*M
M?L4^"O%4$%SH]G\4'^(?V341NL+[4_A/X+\0_%O0@JD,K/\ \)'X'T/8,<G&
M5/0_VT_\'.?P"UOXS_\ !+CQ3XJ\/Q7%_J'[/7Q7\ _'&YTZS 6^O_#BQ>(O
MA9XC:(>OAGP_\4[GQ8Y)RW_".;FRP.?\]G]CK]H;5?V2/VIO@#^TAI5I>:@/
M@_\ %'PQXRO=,L2R2:YX8T75_P#B?Z,DG9O%7APZWX:5ARK.#U%?TWX9NEC/
M#7-\#E^N=<O%Z:N[VE0I-7>C3=-QL]-KIZ7/QSBR^$XORG&XQ^[:+?HI?C9\
MWDKWU=C_ &5J*\;^"_Q@^'GQ]^&7@7XQ?";Q9IOC/X<_$+PYI7B;PCXBTF[F
MET_4M*UQ'N8FW;P(]60?Z/<Z+*1+X=N(WMI=FQ$?V2OYD/V,Y#Q!H&A>*M U
MKPKX@L;?6-!\0Z5J>AZUI]T ]C?Z7JT+Z3JVER@8W1RQN\4J_*S>841E.2O^
M,!\6/"-C\._BK\2? %A?7.I:?X#\>>._!=E=W?\ R$[_ $S0=<U[0LG(P2,?
MSSQ7^M9_P45_;B\!_L!?LE?%K]HWQI=Z<-6T+2+O1/A5X5O;E@?'WQ;UK3KI
M? WA!8T;"6UQKL(N/%MQ"SMX9\&:-XD\87&R"RD _P B34]0O]8O=0U?5KV[
MU+6-4O-3O=7U:[NSJ6I:AJ1R<D^N>.<]\'@"OZ"\"<)C/8Y[CVG_ &(X48SO
M=1E.//*\4]&XQERR:5]8Q=[:?E7B-B<,O[(P=W=.4KKHGIJ[:7W2VNM+-:?Z
MGW_! /Q?J_CS_@D#^Q?K6MX^T6WA;XC^#K7U&D^ OC?\5/ F@9]/^*<\/Z3C
MKSFOY4?^#MOQ%JMY_P % /@AX8EGN1HNA?L?^%[^QLW)&GIJ.O\ QG^+PUK5
M^#G)30M"5\YPVA<U_9U_P2V_9_U3]EO_ ()Z_LE? OQ!8'2O%?@SX/>%[[QI
MHHMDL7T'QOXX>;Q]XZT78<@#P_XJ\7:Y;Y((?R^ K@@?RB_\'=_P!UF#XL_L
MJ_M3V%G=W&A>)?AQXC_9]\373 ?V=H6J^"?%VL_$'P*DA&,2^*4\>>-ASP4\
M/\G+"OGO#_&8)>*698WFBXU*G&7LY)MIN<:]1<MM'>,6E=6Y4Y)R5F_5XCH8
MG_4F"MJJ?"V[4=G33N^]^5V3NWI[K:OYI_P:+^!?#^L_M;_M-_$.^LH+CQ-X
M&^ 6CZ%X?O;I48V$7COQMH3^(/['7^(2?\(/H<#N/GA20RY5/%!*_P"@AOSN
M Z9Y'^?I^E?Y?_\ P;N?MP^#OV,OV^M.T[XI:UIGA[X2_M%>#)/@SXH\1:M=
M06.F^$/%C:IHNM^!/&FM:S,T::)H!\1:.WA)TDEBB9?'[^,9W$/A9\?Z?[.L
M:YQDGGV]/SZ=<]NW->=XQ83&T.-,1B,:I7JTX.G+I91<)6W2<9M-JRNI)K='
M5P)6P[X?II-7BY<R_):^2LO*VM[LLT45X_XT^-WP8^'6O:#X5^(WQ9^&/@'Q
M1XQ$D?A#PWXS\?>$/#'B+Q5Y:E2- T?7=<@N?$!RI0&VBDVLI4J#R/R\^V/6
M4Z)]1_):^"?^"HO_ "C7_;^_[,X_:2_]4WXJK[V3HGU'\EKX1_X*@VL]Y_P3
M:_;[@MSB9OV-/VH-O?/_ !93QR/Y'/X5TY8TLRREMV2K46V]M*]'?U;2^9Q8
M[_<\R7>F_P C_($K_:'_ &=O^3?_ ('?]D>^&G_J&Z)7^+Q7^S-^RYKVC^)/
MV9_V?/$.AZC;ZGI&N_ OX1:OHVI6L_VZSO\ 3=9\$^'Y]'U.-CM$BSHT<T;J
M1N4[BY/*?OGCPKX/@_\ P5/QA'^O\S\S\./][S?_ +<_]*9J_M-?\FW?'[_L
MBWQ0_P#4)UZO\82O]EG]L'Q'HG@S]DW]IWQ7XDU*#2/#^@_L_P#QCUK6=4N&
M"QZ?I>F?#O7YKF9B2,^4JO(HY+,VQ07=:_QIJV\!O]RXO[>SI6?>T)W^[2_J
M'B1_O>4?]O?^E(_V O\ @F+_ ,HW?^"?G_9DO[*7_JA_ E?<[]'^I_DU?$G_
M  3<L+O2_P#@GE^P?IFIVDEC?:9^QS^S)87]G/@R6FHVWP7\"PS0L0<EXYP\
M;8/RL"A (85]MOT?ZG^35_/6/_W[,E_T\J_^I&(]?S/TW!?[GEW^!?\ I*/\
M4#QI_P CCXQ_[&35O_3R:_U9O^"''_*)W]B#_LD(_P#4M\1U_E,^-/\ D<?&
M/_8R:M_Z>37^K-_P0X_Y1._L0?\ 9(1_ZEOB.OZ+\<?^1!P]_P!?)?\ IBJ?
MEGAS_P C?.?\'_MR/U@HHHK^;C]?(A']S(^Z".N,=<>O]<=\U_$/_P '<'[7
M8MXOV<OV'/#.KE6G.H_M$?%NWMRI,B :WX&^%.D>;YLDA+'_ (6?K]QX<E96
MF>S\+SA3'Y1/]L]U>06=O)>7LL-O;P6LEU/<7#*$M0JDL[%L (J@GKG(P,Y
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MQ,G@?Q%$JHS/=?$+76 /EA7_ +2S']_ ^\ .N<],^G],]L5_D4_\$G?VM/\
MABC]OW]G+XZWU^NF>![3QXO@OXHM>W8L-,B^&GCG/@?QKKVMJP9=W@_0=9'B
MQ-PXD\/*?4U_KIK(?F]1&#_(9]O;CKFOP_QAR-Y/Q3/%V7L\_C[>+ZJ=U"JG
MYNT*B>WO2ZZ'Z%P)F2Q>3K!R3YLE?LVWU3YVGZ7YEYVZZ@WW?^ G^;5_C/\
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MSF0JWBV-EPWYZ:9_P:.?\%"9M5@AU;X[?L::9HQO!]JO-+\6_&75-1M=-;.
MNA?\*3\*;V&#G/B_&.A/./V;$YWX,<13_MC'1<:M17E&4:L)SLDKR=/W6TER
M\[FW9)<S2BG\!A\NX[RN^#P5DKW7+RN*OO9/97U26BZ=3\-_VV?^"@?[4O\
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M*'],?^"_^N? 76O@)_P3_O?C[+;^)/V:M;_X*._ N]^*2Z<GBW7=+U[X8_\
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M.3^9P,_AG'YU.-FW ';..^#WSCIC.01ZGMS_ "&S_P#!&K_@FJG_  61T_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OCULAR
THERAPEUTIX, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001393434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5560161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15
Crosby Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bedford<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">357-4000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OCUL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2530039d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocutx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ocul-20251104.xsd</File>
    <File>ocul-20251104_lab.xml</File>
    <File>ocul-20251104_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2530039d1_8k.htm">tm2530039d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2530039d1_8k.htm": {
   "nsprefix": "ocul",
   "nsuri": "http://ocutx.com/20251104",
   "dts": {
    "schema": {
     "local": [
      "ocul-20251104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ocul-20251104_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ocul-20251104_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2530039d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://ocutx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2530039d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-11-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2530039d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ocutx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-25-105914-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-105914-xbrl.zip
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M^L<(<&1T$=#;!%X!O[/2YI..XP]=T',29X$,B26NAQA3D";XQH$?)ZD8N<&
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M 0'UT3Y;V2Y[=?7'Y]?IZ-4+_)>Y RZBE.L92PM7F&7 MKT&N[4-.N3!('%
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M7 P:?\#^K9,"G9 T0DO-IUCW2/H@QZ(DU=:;)9!%(7;Y']ZZD"B6!-XN>HL
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M-U1N]O'F]96$2U5F(8>OR%%GHPWC1;VY  662O6B%/^E7JMV5L$?7@#PASW
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M-KOQO'S,C<=B+#F\@!DHE*Q-A?JJC8#N"J WJ@B'>BSH9/O@+APH.UN;JS?
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M+F5>XI0U!S(":I&L4:ZK=7IBE\?/2XT-Y JTA/E\@'D&(H6R_5:S822+<F2
M9)8\0XT[-1%;43^A"@Z/!_Y JKJ.A3'5 ^I,13P:\735_C>J]TUU?^^"_'"!
MG(EM+B;H^X1780F_QQY(@54$!=^/'6FET.J,0Z406Q7W#JTN>O=J?J#]O?LY
M@C867 6[\%N.H'+3RF+#V/ <%:PL3.E2K<S8#$9#AP:SN7E,OF@9'UCMSPKM
MLJS/3:LLA[L64S).X3U6<-GS8]9F#JU@) T,?KK12'5AS<<F]9H_0^H5XX]*
MY E+KFC.9-?JWT_,=)NUF4C.VJ0,2ZV'B)DRH\PJ?MS.SH_[N/VX]XS-B06A
M.2YC7Q3/$HW6:N&X;[V"QYB,W/%=*^NZ7GME_8P5=[-<#W-M/Q<&UY(ET;6[
MU2* BJT7%3T1I>8+W]!@FF778,H,6Z-A_,F>Q[*K%7_>:^XT6X>!Y!0!GE :
M#0 ;2.8ZPH^Q5T[,4X15DC %2=W!0/=B*,ATN^\3]9R]\;T,^] .@ZA'7A@D
MZ;K5;TZG+8&=A'5J*8\=":)0@LFG@,X[2PH[T 7[O1#K" -J:-L+<.K5#1)P
MH&;NT?M&4]!+X+]C::I9D;'D%:TZ.>3&30A<JF$[;HP!Z(!&H8MM\Z8!V$ N
M8SCWII2(%8ALHIH *[^47A(I$TMU E2>U-ZXG9HX0 <E*/)_*IT% #J><'=F
ME8P2959G7TJ(46$60<U]Y=?,8YU(]3:C$ESE!%-=8);>);]7U2;E;[%6P&[^
M9BR.<O@-LE#-="5>J[-/T(D.Z*G\>E-0"\985Z4:>% R=H!5D_S^*LY\IM94
M4FF NE\>)PJAFUZ'ZLT$ 4=%M,@#"$ISI+R'QL&+7>1,1IKIK^#AV<WL+MQ?
M-D$$:M5^-3E1^3Q?OCZ5DP:X2/,:\'3:Z8CIOT;F\-95WI!'WF.*9UA>3Y ^
M[A>,C49#J1+7J$N,[JB'-(C;R8<&LS2CZ"#I8?#R@D>6B"?GQ"3S])5M!TL]
MU[KXQ53"+P2SLO-7LV?,(C0=L!.KOP<J1E-KWC)S/C&2;L!8TI<QMK$HSII&
M;/=X% ?UA<PPRLL(ES/1F5Q*MF5@\](%SH086NI[/U]HKZ%/4.DG-*Y(=0'%
MG-8A]E&GL7O%VD9LE6?D#X\?#$TW3Y NM::1+A,938#=T>#T6]^35>S,34+/
MT.8-1Y!\W5F/^;Q^IRU2V'/FN6,0L)YRR5&"HHN-,ON@<'*W;.(P8"4/AQQB
MFH+V$T>ZM3MU=L=]8K?\@((U_))AD/7A<BD%8DS)4CAC,!A0U#P(<M,U'T$6
M%WIP8@26>7T2C=%GB,-1!G3B4'DFT7Q&!DUPP/B9J2DWR8?SAK;RW(**..1&
M5RHYP_Y*_@U4]7"^&.  %;TH!%<B#\^R3&2#*'HK;REJBW5HO^J0;,=J1(9;
MR0%@EZ*9I$?#/-7X<D\F$U_[2=P;UP^LAAJSN:G4%50UX319)'GS?-!LL?0W
M;QB$?U;#:C"N%:LDCEP8;0=)SGA#T!5"9(*UUO,*HJT^4+R,ZN6C&,VL"J*
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M^4";N*$7;SZ=__LU_O#[]8?WK_\_4$L! A0#%     @ 83ID6Y<_ROLF P
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M,#,Y9#%?.&LN:'1M4$L! A0#%     @ 83ID6^Q%[Z$(.   K\\! !8
M         ( ! "@  '1M,C4S,# S.60Q7V5X.3DM,2YH=&U02P4&      4
,!0!) 0  /&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tm2530039d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ocul-20251104.xsd" xlink:type="simple"/>
    <context id="AsOf2025-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001393434</identifier>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-11-04" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-11-04" id="Fact000004">0001393434</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-11-04" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-11-04" id="Fact000010">2025-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-11-04" id="Fact000011">OCULAR THERAPEUTIX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-11-04" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-11-04" id="Fact000013">001-36554</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-11-04" id="Fact000014">20-5560161</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-11-04" id="Fact000015">15 Crosby Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-11-04" id="Fact000016">Bedford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-11-04" id="Fact000017">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-11-04" id="Fact000018">01730</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-11-04" id="Fact000019">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-11-04" id="Fact000020">357-4000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-11-04" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-11-04" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-11-04" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-11-04" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-11-04" id="Fact000025">Common     Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-11-04" id="Fact000026">OCUL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-11-04" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-11-04" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
